Plain-English translation of NCT04162353 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing BCMA-CD19 cCAR, a new type of immunotherapy that uses your own T cells (immune cells) to fight blood cancer. The treatment is designed to attack cancer cells in two different ways at once, targeting proteins called BCMA and CD19 that appear on myeloma and lymphoma cells. Because it hits two targets simultaneously, researchers hope this approach will be more effective than treatments that only target one protein.
Multiple myeloma and plasmacytoid lymphoma are difficult to treat because cancer cells can be different from each other and can develop resistance to single-target therapies. This medication aims to overcome that problem by attacking cancer cells through two different pathways at the same time, which may prevent the cancer from escaping the immune response.
You likely qualify if…
You likely don't qualify if…
In this early-stage trial, you would receive the treatment in doses that start low and gradually increase based on safety. Your own T cells would be collected, engineered in a laboratory to recognize and attack your cancer using the new medication, and then reinfused into your body. You would be closely monitored with blood tests and exams to see how well the treatment works and to watch for any side effects. The study is small (enrolling around 12 people) and is still in its earliest testing phase.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
China
Phase
Safety & dosing
Sponsor
iCell Gene Therapeutics
Collaborators
iCAR Bio Therapeutics Ltd., Peking University Shenzhen Hospital
Enrollment target
~12 participants
Started
July 2019
Primary completion
July 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Last updated on clinicaltrials.gov in September 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Kevin Pinz, MS
Peking University Shenzhen Hospital, China
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.